1. Search Result
Search Result
Isoforms Recommended: IKK-α
Results for "

IKKα

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

3

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123942
    Diprovocim
    Maximum Cited Publications
    14 Publications Verification

    Toll-like Receptor (TLR) TNF Receptor p38 MAPK NF-κB Inflammation/Immunology Cancer
    Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC50=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC50=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses .
    Diprovocim
  • HY-P1938

    Bacterial Infection Inflammation/Immunology
    Cyclo(L-Pro-L-Val) is an antimicrobial and anti-inflammatory agent. Cyclo(L-Pro-L-Val) has toxic activity against plant pathogens such as R. fascians LMG 3605, and its potency may be comparable to that of Chloramphenicol (HY-B0239). Cyclo(L-Pro-L-Val) can inhibit the phosphorylation of IKKα, IKKβ, NF-κB, etc., and the activation of iNOS and COX-2, thereby exerting anti-inflammatory activity. Cyclo(L-Pro-L-Val) can be used in the research of biopesticides in the agricultural field, as well as in the research of inflammation-related diseases .
    Cyclo(L-Pro-L-Val)
  • HY-69047

    IKK Others
    6-Chloro-7-deazaguanine is an inactive molecule of IKK (lacking the critical 5-cyano group). IKKβ and IKKα are core molecules in the canonical NF-κB pathway and non-canonical NF-κB pathway, respectively .
    6-Chloro-7-deazaguanine
  • HY-W067427
    BAY32-5915
    1 Publications Verification

    IKK Cancer
    BAY32-5915 is a potent IKKα inhibitor with an IC50 value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .
    BAY32-5915
  • HY-169053

    IKK NF-κB Cancer
    SU1261 is an IKK inhibitor with Ki values of 10 nM and 680 nM for IKKα and IKKβ, respectively. SU1261 can inhibit non-canonical NF-κB signaling in U2OS osteosarcoma cells .
    SU1261
  • HY-135366

    IKK Inflammation/Immunology
    HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .
    HPN-01
  • HY-W009338
    H-Val-Tyr-OH
    1 Publications Verification

    Val-Tyr

    IKK NF-κB Inflammation/Immunology Cancer
    H-Val-Tyr-OH (Val-Tyr) is a dipeptide formed by the connection of valine and tyrosine via a peptide bond. H-Val-Tyr-OH is a potential IKKα inhibitor and can be used in the research of cancer and inflammatory diseases .
    H-Val-Tyr-OH
  • HY-P1847A

    NF-κB Inflammation/Immunology
    IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .
    IKKγ NBD Inhibitory Peptide TFA
  • HY-107592

    IKK STAT Apoptosis Inflammation/Immunology Cancer
    ACHP (compound 4j) is a selective and orally active IκB kinase inhibitor with IC50 values of 8.5 nM and 250 nM for IKKβ and IKKα, respectively. ACHP can effectively inhibit the STAT3 signaling pathway and induce cancer cell cycle arrest and apoptosis. ACHP shows anti-inflammatory activity in a mouse ear edema model. ACHP can be used in anti-inflammatory and anti-cancer (such as multiple myeloma and leukemia) studies .
    ACHP
  • HY-P1847

    NF-κB Cancer
    IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .
    IKKγ NBD Inhibitory Peptide
  • HY-175521

    HIF/HIF Prolyl-Hydroxylase IKK NF-κB Apoptosis Reactive Oxygen Species (ROS) Inflammation/Immunology
    HIF-1α-IN-8 is an orally active HIF-1α inhibitor, with an IC50 of 2.02 μM. HIF-1α-IN-8 significantly suppresses the expression of inflammation factors of IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells. HIF-1α-IN-8 inhibits HIF-1α/IKKα/NF-κB signaling pathway and reduces the expression of blood-brain barrier permeability-related proteins. HIF-1α-IN-8 reduces brain water content and oxidative stress level in mice with high altitude cerebral edema (HACE) model. HIF-1α-IN-8 can be used for the study of high altitude cerebral edema (HACE) .
    HIF-1α-IN-8
  • HY-136393

    IKK Inflammation/Immunology
    IKK-IN-4 is a potent and selective IkappaB kinase 2 (IKKβ orIKK2) inhibitor, with IC50s of 45 and 650 nM for IKKβ and IKKα, respectively .
    IKK-IN-4
  • HY-136392

    IKK Inflammation/Immunology
    IKK-IN-3 is a potent and selective IkappaB kinase 2 (IKK2 or IKKβ) inhibitor, with IC50s of 19 and 400 nM for IKK2 and IKK1 (or IKKα), respectively .
    IKK-IN-3
  • HY-E70831

    IKK Cancer
    IκB kinase α (IKKα), one of the two catalytic subunits of the IKK complex involved in NF-κB activation, also functions as a molecular switch that controls epidermal differentiation. IKKα Recombinant Human Active Protein Kinase is a recombinant IKKα protein that can be used to study IKKα-related functions .
    IKKα Recombinant Human Active Protein Kinase
  • HY-124865

    MAP3K IKK Cancer
    MAP3K14-IN-1 (Compound 173) is a MAP3K14 (NIK kinase) inhibitor with an IC50 of 1.8 nM. MAP3K14-IN-1 inhibits the autophosphorylation of MAP3K14 kinase. MAP3K14-IN-1 reduces the level of phosphorylated IKKα in cancer cells. MAP3K14-IN-1 inhibits the proliferation of multiple myeloma cells. MAP3K14-IN-1 can be used in research related to multiple myeloma .
    MAP3K14-IN-1
  • HY-180829

    HDAC NF-κB IKK COX NO Synthase Inflammation/Immunology
    HDAC6-IN-71 (Compound 24) is a HDAC6 inhibitor with IC50 values for HDAC6 and HDAC1 of 13.68 and 443.12 nM respectively. HDAC6-IN-71 effectively inhibits the production of NO by mouse macrophages, with its IC50 being 2.31 μM. HDAC6-IN-71 inhibits the HDAC6-NF-κB signaling pathway, reduces the levels of phosphorylated IκB-α and IKK-α/β, and suppresses the expression of downstream inflammatory proteins COX-2 and iNOS. HDAC6-IN-71 significantly alleviates ulcerative colitis in mice .
    HDAC6-IN-71
  • HY-180119

    IKK NF-κB Autophagy Cancer
    IKKβ-IN-5 is an orally active and selective IKKβ inhibitor with an IC50 of 7.5 nM. IKKβ-IN-5 directly inhibits IKKβ phosphorylation and attenuates NF κB mediated inflammatory and survival signals while promoting autophagy flux. IKKβ-IN-5 exhibits a 6-fold selectivity forIKKβ over the homologous kinase IKKα. IKKβ-IN-5 exerts robust antiproliferative effects through a dual mechanism involving G₂/M phase cell cycle arrest and autophagy activation, even under inflammatory stimulation in vitro. IKKβ-IN-5 demonstrates favorable pharmacokinetics and suppresses tumor growth in vivo. IKKβ-IN-5 can be used for colorectal cancer and potentially other inflammation driven malignancies research .
    IKKβ-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: